Fabtech swings to ₹4.2 Cr consolidated Q1 profit YoY; revenue up just 10%, dips QoQ on seasonality
revenue +10.26% · margins expanding
₹74.98 Cr
+10.26% YoY
₹4.21 Cr
5.39%
+14.3pp YoY
₹0.95
Fabtech Technologies posted a clean year-on-year turnaround in Q1 FY27: consolidated PAT of ₹4.21 Cr against a ₹6.13 Cr loss a year ago, on revenue of ₹74.98 Cr (+10.3% YoY). Net margin swung to ~5.6% from -8.9%, and — importantly — the improvement is understated by the headline, because the year-ago loss was actually cushioned by a ₹1.77 Cr exceptional gain (sale of a 51% LLP stake). Strip that out and the underlying swing, from roughly a ₹7.9 Cr operating loss to a ₹4.2 Cr profit, is larger than the reported one. This quarter carries no exceptional item.
Q1 FY-2027 vs prior quarters
The sequential picture looks weak on the surface — revenue -52.7% and PAT -80.9% versus Q4 FY26 — but that is a seasonality artifact, not deterioration: Fabtech is a turnkey pharma-engineering project business whose revenue is heavily back-half/Q4-weighted (Q1 FY26 was ₹68 Cr against a ₹159 Cr Q4). The QoQ drop should be read as the normal start-of-year trough, which is why YoY is the right lens here. The consolidated result also leans on the overseas arm: standalone PAT was only ₹1.06 Cr (itself a turnaround from a ₹9.16 Cr loss), while UAE subsidiary Fabtech Technologies LLC contributed ~₹3.81 Cr — a >3x divergence readers will notice, so the consolidated figure is the fair basis.
The stock went into the print at ₹149.73, down 5.1% over the past month of trading.
Management projects approximately 25% revenue growth for FY27, driven by a strong order book exceeding ₹900 crores and expansion in key geographies like the GCC and Africa. They guide for an improvement in PAT margins to the 9.5% to 10.5% range, with a long-term FY28 target of 12-14%. The strategic focus is on discipli
— This quarter: missed
Against management's own FY27 guidance — ~25% revenue growth and a 9.5-10.5% PAT margin, backed by a >₹900 Cr order book and GCC/Africa expansion — Q1 is running behind on both counts (+10% growth, 5.6% NPM), consistent with a back-half-loaded year but a gap that H2 execution must close. No brokerage publishes quarterly consensus for this recently-listed micro-cap, so there is no street bar to beat. Concurrent board actions align with the confident tone struck on the Q4 concall: a ₹0.60/share FY26 final dividend, chairperson re-appointment, and an approved ODI of up to ₹24 Cr into the UAE subsidiary plus a new Saudi step-down entity — capital being pushed toward the same overseas geographies now carrying the P&L. The item to watch is receivables at ₹214.9 Cr against ₹75 Cr of quarterly revenue.
W1
Revenue must accelerate in H2 to hit the guided ~25% FY27 growth — Q1 is at only +10.3% YoY (₹74.98 Cr).
W2
PAT-margin recovery toward the guided 9.5-10.5% band — Q1 NPM is 5.6%.
W3
Execution of the >₹900 Cr order book and ramp of the new Saudi step-down subsidiary and UAE ODI (₹24 Cr).
W4
Receivables at ₹214.9 Cr vs ₹75 Cr quarterly revenue — collection cycle to monitor.
Clean digital filing, limited-review (unaudited). Consolidated PBT 5.2331 Cr is after share of associate loss ₹0.02 Cr; PAT attributable to owners 4.2104 Cr, NCI ~nil. No exceptional item this quarter; year-ago Q1 PAT (-6.1259 Cr) INCLUDED a +1.7748 Cr exceptional gain from a 51% LLP stake sale, so adjusted turnaround is larger. Consolidated>standalone due to UAE subsidiary (~₹3.81 Cr PAT). Values converted ₹Lakh→₹Cr.
Profitable turnaround, margin miss; geopolitical headwinds offset by Saudi localization
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Reaffirmed FY27 growth guidance (20-25%) and order book (₹900 Cr) intact; Q1 margin miss offset by seasonality argument; no guidance cut, but no upgrade.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Profitable turnaround and structural margin improvement (46.7% contribution margin) are genuine, but Q1 net profit margin (5.4%) fell 400+ bps short of prior 9.5-10.5% guidance, and -80.9% QoQ PAT decline exposes seasonality risk. FY27 20-25% growth guidance now requires 30-35% H2 growth; achievable but tight. Saudi localization and Africa expansion are tangible value drivers, but geopolitical delays and working-capital drag warrant caution near-term.
₹75 Cr
Revenue · +10.3% YoY₹4.2 Cr
Reported PAT · +168.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q1 10% YoY revenue growth, strong profitability turnaround
METDelivered ₹75.0 Cr (+10.3% YoY), ₹4.2 Cr profit vs ₹6.13 Cr loss prior year
Contribution margin expanded 900 bps to 46.7% from 37.6%
METCOGS declined 3.35% YoY despite 10% revenue growth; margin expansion confirmed
PAT margins to improve to 9.5-10.5% (prior FY26 guidance)
OVERSTATEDQ1 NPM 5.4%; guidance now stated as 9-11% (wider, floor down 50 bps to 9% from 9.5%)
Order book ₹900+ Cr with strong visibility over 2 years
MET900+ Cr confirmed; active inquiries ₹9,300 Cr, hot leads ₹3,800 Cr—credible pipeline
Saudi Arabia 130% YoY growth to ₹17.14 Cr; Africa (Morocco+Kenya) ₹27.94 Cr
METSegment performance aligns; localization strategy (51% stake in SACE) tangible; civil order closure recent
No order cancellations due to geopolitical delays; only timing pushes
METCalls acknowledge delays in conversions (Q1 vs expected), but no cancellations stated; client engagement ongoing
FY27 guidance 20-25% organic growth intact
METQ1 10% growth means H2 needs 30-35% growth to hit mid-point; feasible but tight; reaffirmed not upgraded
Earnings quality
What changed since the last call
Localization in Saudi Arabia via SACE acquisition
UpgradeNow hold 51% stake in licensed local platform; first civil order closed post-call; moves Fabtech from vendor to partner in MEP/civil
Africa expansion from negligible to ₹28 Cr (Morocco+Kenya+Botswana)
UpgradeMorocco and Kenya contributed ₹27.94 Cr in Q1 (zero a year ago). Botswana vaccine facility (₹31.23 Cr) won in quarter. Structural geographic diversification evident.
PAT margin guidance floor softened from 9.5% to 9%
DowngradePrior FY26 guidance was 9.5-10.5%; current is 9-11%. Lower bound cut 50 bps; offset by upper bound raise to 11%. Net: slight widening downward.
FY27 growth guidance shifted from 'approximately 25%' to '20-25% range'
NeutralPinpointed ~25% became range with lower bound. Maintains upside potential but acknowledges execution risk on geopolitical delays.
The Q&A
Analyst questions (Vignesh Iyer) pressed hard on geopolitical war impact on working capital and execution timing. Management acknowledged delays but held firm on order book integrity and H2 recovery. Shareholder (Vikas Gupta) raised stock price below IPO despite earnings delivery; management deflected (stock price beyond control) but committed to IR roadshows and media coverage strategy.
Stock price & investor confidence — Vikas Gupta, shareholder
PartialManagement cannot control stock price directly. Focused on business delivery (10% growth, profitable, margins in place). Committed to IR roadshows, media strategy, Vision 2030/2035 document to attract right investors.
Trade receivables & cash conversion — Chandrashekhar Daga
AnsweredMost backed by LC/CAD; stuck due to (1) retention periods 1-2 years (~10-15% of value), (2) LC terms at documentation (30-40 days post-delivery). Saudi major contract (₹120 Cr) driven receivable; delivery by Q3 expected to release collections.
UAE weakness vs Saudi strength — Chandrashekhar Daga
PartialUAE focused on high-tech (cell-gene therapy, nutraceuticals) not generic pharma; projects selective. Delays due to geopolitical, not cancellations. UAE still valuable hub for customer demos. Normalization depends on geopolitical resolution.
Order book split by segment — Chandrashekhar Daga
PartialSplit not given (complex). Majority pharma+biotech. Vaccines: ₹30+ Cr Botswana, ₹7M Saudi BioBago. Repeat customers 10% (strategic shift to diversify new customer wins; stickiness after delivery).
Five-year vision and execution milestones — Raju Pathak
PartialPositioned in right markets (Africa, Saudi, SE Asia). Selective talent acquisition. Disciplined order selection. Indicators: order pipeline closure rate, margin protection, geographic diversification, acquisition integration.
Geopolitical impact on execution and working capital — Vignesh Iyer
AnsweredWC cycle normal ~120 days. Receivables ₹210-214 Cr offset by ₹110 Cr advances from customers. Shipment delays (₹20-22 Cr at port) are main drag, not WC philosophy change. Teams on ground executing strict deadlines.
Tender type and escalation clause protection — Vignesh Iyer
AnsweredContracts include RMC escalation clause >5% pass-through provision. Offers valid 2-3 weeks (ensure customer seriousness). Customers balanced; understand Fabtech is partner not vendor. Mutual interest in on-time delivery.
Accounting method—milestone vs percentage completion — Niraj Chhajer
PartialUnder evaluation; rework on agreements needed. New contracts being drafted to support % completion method. Auditors also evaluating. Implementation gradual (existing contracts stay milestone-based; future contracts transition).
Long-term investor strategy and institutional engagement — Niraj Chhajer
AnsweredVision 2030/2035 document in progress. Acknowledged market-cap chicken-egg issue (need ₹1,000 Cr+ to access large funds). Agreed to target family offices, AIF, PMS below ₹1,000 Cr market cap; pivot to micro/small cap funds once larger.
IPO proceeds deployment and inorganic growth — Niraj Chhajer
AnsweredSaudi acquisition (SACE) done; 51% stake acquired; first civil order closed last week. European acquisition in due diligence (taking time to ensure strategic fit). Expect both completed by FY27 year-end.
Margin expansion sources—gross vs operating leverage — Raju Pathak
AnsweredBoth. Evaluating China procurement (customer-comfortable) for gross margin lift. Fixed costs controlled; operating leverage kicking in with revenue growth. Q1 shows both factors working.
Guidance
FY27 organic growth 20-25% (from ~25% prior)
MediumQ1 delivered 10.3%; H2 needs 30-35% growth to hit mid-point. Order book visible; geopolitical delays but no cancellations. Feasible if H2 executes.
PAT margin 9-11% (from 9.5-10.5% prior)
MediumQ1 delivered 5.4% (400+ bps miss). Guidance floor cut to 9% from 9.5%. Seasonality argument (Q1 light) valid, but execution risk on margin ramp needed in H2.
₹24 Cr investment into Saudi platform (SACE); additional into FT Institutions (unspecified)
HighDeployed post-IPO; dedicated to localization strategy, not organic growth capex model discussed.
Risks the call surfaced
Customer concentration
HighSaudi customer (unnamed) accounts for ~₹72.57 Cr of Q1 revenue. Receivables stuck during installation. Project delivery by Q3 expected, but execution slip would hit collections and Q2/Q3 revenue.
Geopolitical execution risk
MediumGeopolitical conditions (West Asia war) have delayed finalization of large orders (Q1 saw pushes from Q0 into Q2+). Investor slowed decision-making (not canceled). 78% of revenue from MENA/GCC/Africa; concentrated exposure to war-affected regions.
Margin guidance miss & execution risk
HighQ1 net profit margin (5.4%) fell far short of 9.5-10.5% prior FY27 guidance. Management attributes to Q1 seasonality (light quarter by design in EPC model). If true, H2 must deliver 9-11% margins to hit range. If false (structural), guidance at risk.
Working capital drag—shipment delays
MediumShipment availability constraints beyond Fabtech's control have left ₹20-22 Cr of goods at port end-Q1. Delays cash conversion, ties up working capital, pushes revenue recognition into Q2. Not a demand issue but logistics friction.
Repeat customer dependency shift
LowRepeat customers dropped to 10% of current order book (from higher % in prior years). Strategic shift to diversify and grow pipeline. Risk: if new customer quality or execution falters, repeat customer stickiness loss may hurt future orders.
Management
Score 7/10. Clear, grounded; CEO laid out seasonality argument transparently. CGO and Head IR articulate on strategy and numbers. Defensive on stock price (beyond control), but committed to IR outreach and Vision 2030 document. Track record solid: reaffirmed FY27 guidance (20-25% growth, 9-11% PAT margin). No prior targets cut. Q1 margin miss (5.4% vs 9.5-10.5%) addressed via seasonality argument (credible for EPC model); but execution risk on H2 margin ramp remains.
1 · Q2-Q3 FY27
Saudi Arabia ₹120 Cr project delivery acceleration; cash conversion expected after Q3 delivery milestone
2 · H2 FY27
Large deferred orders (pushed from Q1 by geopolitical delays) finalize; conversion expected; 30-35% growth needed to hit FY27 target
3 · Q3-Q4 FY27
European acquisition closing (currently in due diligence); adds capability + customer reach
Saudi localization and Africa expansion are tangible value drivers, but geopolitical delays and working-capital drag warrant caution near-term.